The US Food and Drug Administration (FDA) has issued a Class I recall for NAD+ due to elevated endotoxin levels, posing a serious risk of severe inflammatory reactions or sepsis if administered.
The US Food and Drug Administration (FDA) has issued a Class I recall for NAD+ due to elevated endotoxin levels, posing a serious risk of severe inflammatory reactions or sepsis if administered.
True or False: Donepezil, rivastigmine, and galantamine are all FDA-approved acetylcholinesterase inhibitors indicated for the treatment of mild to severe Alzheimer disease.
True or False: Donepezil, rivastigmine, and galantamine are all FDA-approved acetylcholinesterase inhibitors indicated for the treatment of mild to severe Alzheimer disease.
True or False: Anti-amyloid monoclonal antibody injectables, such as lecanemab and aducanumab, are FDA-approved disease-modifying treatments that can completely halt the progression of Alzheimer's disease.
True or False: Anti-amyloid monoclonal antibody injectables, such as lecanemab and aducanumab, are FDA-approved disease-modifying treatments that can completely halt the progression of Alzheimer's disease.
